Archives
- o2h Ventures Proud to be Shortlisted for the EISA Impact Award for a Second Year Running! 7 June, 2024
- o2h Ventures Announces Seed Investment in AscendBio, A Company Advancing Therapies for Metabolic and Respiratory Diseases 3 May, 2024
- o2h Ventures Invests in Vesynta, a Company Developing an AI Software to Maximise Therapeutic Potential and De-risk drug development 23 April, 2024
- o2h Ventures invests in ClotProtect, a Company Developing Treatment to Improve Bleeding and Survival Outcomes 22 April, 2024
- o2h Ventures Invests in Stratosvir – Advancing Viral Immunotherapy For Late-Stage Cancer 17 April, 2024
- o2h Ventures Announces SEIS Investment in Innovative mRNA-Based Hearing Loss Treatment Company, CamGene Therapeutics 5 April, 2024
- Pioneering innovation in biotech investments via o2h Ventures’ human health S/EIS funds 20 February, 2024
- Fuelling academic innovation and fostering entrepreneurship 8 January, 2024
- o2h Ventures – Embracing autumn with exciting updates and amazing achievements! 12 October, 2023
invest in the growth potential of UK life science & AI